BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33241594)

  • 1. Simulation model of disease incidence driven by diagnostic activity.
    Westerberg M; Larsson R; Holmberg L; Stattin P; Garmo H
    Stat Med; 2021 Feb; 40(5):1172-1188. PubMed ID: 33241594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort.
    Bergengren O; Westerberg M; Holmberg L; Stattin P; Bill-Axelson A; Garmo H
    JAMA Netw Open; 2021 May; 4(5):e219444. PubMed ID: 33999165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data.
    Karlsson A; Jauhiainen A; Gulati R; Eklund M; Grönberg H; Etzioni R; Clements M
    PLoS One; 2019; 14(2):e0211918. PubMed ID: 30763406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
    Jonsson H; Holmström B; Duffy SW; Stattin P
    Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
    Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
    Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
    Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
    Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
    J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
    Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
    Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
    Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ONCOTYROL Prostate Cancer Outcome and Policy Model: Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening.
    Mühlberger N; Kurzthaler C; Iskandar R; Krahn MD; Bremner KE; Oberaigner W; Klocker H; Horninger W; Conrads-Frank A; Sroczynski G; Siebert U
    Med Decis Making; 2015 Aug; 35(6):758-72. PubMed ID: 25977360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
    Shen X; Kumar P
    J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
    Lee DJ; Mallin K; Graves AJ; Chang SS; Penson DF; Resnick MJ; Barocas DA
    J Urol; 2017 Dec; 198(6):1230-1240. PubMed ID: 28552708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
    Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for prostate cancer: an updated review.
    Marta GN; Hanna SA; Fernandes da Silva JL; Carvalho Hde A
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):101-8. PubMed ID: 23259431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
    Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.
    Auvinen A; Moss SM; Tammela TL; Taari K; Roobol MJ; Schröder FH; Bangma CH; Carlsson S; Aus G; Zappa M; Puliti D; Denis LJ; Nelen V; Kwiatkowski M; Randazzo M; Paez A; Lujan M; Hugosson J
    Clin Cancer Res; 2016 Jan; 22(1):243-9. PubMed ID: 26289069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.